Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Sales of Investments

Cash received from selling or redeeming investments.

Generate Biomedicines, Inc.NASDAQ: GENB

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments of $65M in Q1 FY2026

Q1 FY2026 sales of investments was $65M.

Context

  • Sales of investments amounted to 893.7% of revenue in FY2025, down 224.2 pp from a year earlier.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$65M— QoQ
Last fiscal yearDec 2025
$285.01M+24.6% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+24.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
285.01M USD
Year-over-year change
+24.6%
1-year CAGR
+24.6%

Sales of Investments vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 sales of investments of $285.01M is the largest of the 5 companies compared; the peer median is $159.76M.
  • Its year-over-year change of +24.6% is the highest of 4, against a peer median of -56.8%.
  • Sales of investments amounts to 893.7% of revenue for GENB, versus a peer median of 315.9%.
GENB Competitors Peer median
Sales of Investments for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GENBGenerate Biomedicines, Inc.FY2025$285.01M +24.6%—893.7%
STROSutro Biopharma, Inc.LTM Mar 2026$263.81M -56.8%+18.0%264.9%
ABCLAbCellera Biologics Inc.LTM Sep 2026$249.02M -57.5%-0.3%367.0%
ABSIAbsci CorporationLTM Mar 2026$70.5M -52.5%+140.4%3839.9%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding GENB) $159.76M-56.8%+18.0%315.9%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.